### **1** Supplementary Appendix

2	Table of Contents	
3	List of Investigators	2
4	Supplementary Methods	3
5	Supplementary Figures	7
6	Supplementary Tables	21
7	Supplementary References	24
8		

- 10 List of Investigators
- 11
- 12 Annika Rössler<sup>1,\*</sup>
- 13 Antonia Netzl<sup>2,\*</sup>
- 14 Ludwig Knabl<sup>3</sup>
- 15 Helena Schäfer<sup>1</sup>
- 16 Samuel H. Wilks<sup>2</sup>
- 17 David Bante<sup>1</sup>
- 18 Barbara Falkensammer<sup>1</sup>
- 19 Wegene Borena<sup>1</sup>
- 20 Dorothee von Laer<sup>1</sup>
- 21 Derek Smith<sup>2,#</sup>
- 22 Janine Kimpel<sup>1,#</sup>
- 23
- <sup>1</sup>Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of
   Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria
- <sup>2</sup>University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK
- <sup>3</sup>Tyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria
- 28
- 29 \*Contributed equally
- 30 <sup>#</sup>Corresponding authors:
- 31 Derek Smith (djs200@cam.ac.uk) and Janine Kimpel (Janine.Kimpel@i-med.ac.at)
- 32
- 33

#### 34 Supplementary Methods

35

#### 36 Patient Characteristics

37 Patients were divided into three groups depending on their numbers of exposure to 38 infection/vaccination. Single exposure was defined as unvaccinated with a single infection (n=10 39 infected during first wave (wild type), n=10 alpha, n=8 beta, n=7 delta, n=18 BA.1 omicron, and n=12 40 BA.2 omicron. Double exposure was defined as either unvaccinated individuals with two subsequent 41 infections (n=15 with pre-omicron infection followed by BA.1 re-infection and n=3 with pre-omicron 42 infection followed by BA.2 re-infection) or two vaccine doses without any history of infection (two 43 homologous doses of mRNA-1273 (n=10), ChAdOx-S1 (n=10) or BNT162b2 (n=11) respectively or 44 heterologous vaccination with ChAdOX-S1 as first and BNT162b2 as second dose (n=10)). Three or 45 more exposures were defined as vaccinated individuals with breakthrough infections (n=6 with delta breakthrough after two doses of ChAdOx-S1, n=22 with delta breakthrough after two doses of 46 47 BNT162b2, n=14 with two or three vaccine doses and BA.1 omicron breakthrough, and n=8 with two 48 or three vaccine doses and BA.2 omicron breakthrough) or vaccinated individuals with a previous pre-

- 49 omicron breakthrough followed by a BA.1 omicron breakthrough (n=11).
- 50

## 51 Map Diagnostics

52 Map diagnostic tools were used to assess the quality of the antigenic map with P.1.1 reactivity adjusted

- 53 by -1 on the  $log_2$  scale (Figure 2, Supplementary Figure S2).
- 54

# 55 Map Dimensionality

First, a dimensionality test was performed with *Racmacs'*<sup>1</sup> *dimensionTestMap* function in dimensions 1 to 5 with a test proportion of 0.1, the minimum column basis set to "none", the fixed column bases of the current map, and 100 replicates per dimension with 1000 optimizations per replicate. The Root Mean Square Error RMSE between measured and predicted titers was used to judge which dimensionality best represents the antigenic relationships of the titer data. Figure S3 shows that the error between predicted and measured titers is smallest in two dimensions, indicating that the titer data is best represented by a 2D map.

63

# 64 Correlation of fitted and measured titers

Next, the correlation of fitted and measured titers of the map was assessed by converting map distances into log<sub>2</sub> titers. As one antigenic unit in the map corresponds to one two-fold dilution in the neutralization assay, subtracting the Euclidean distance for each serum-antigen pair from the maximum log<sub>2</sub> titer of the specific serum gives log<sub>2</sub> titers.

69 Doing this for each serum group revealed good correlation of measured and fitted log<sub>2</sub> titers (Figure

54). In the omicron convalescent serum groups, measured titers exceeded fitted titers slightly. A large

number of below detectable titers, however, impairs the accurate positioning of a serum and explains
 the larger difference between measured and fitted titers in the omicron convalescent compared to

- 73 other serum groups.
- 74

#### 75 Map robustness

76 Bootstrapping on sera and antigens was performed to determine how robust the map is to 77 measurement noise and the exclusion of samples and antigen variants. Racmacs' <sup>1</sup> bootstrapMap 78 function with the "noisy" method was used to simulate measurement noise, doing 1000 repeats and 79 100 optimizations per repeat, bootstrapping both sera and antigens with normally distributed 80 measurement noise with a standard deviation of 0.7 added to either the titer, the antigen or both 81 (Figure S5). The same function and optimization routine was used to test the impact of serum and 82 antigen exclusion on the map, using the "resample" method with antigen and titer noise standard 83 deviation of 0.7, and resampling only antigens, sera or resampling both (Figure S6). To test the 84 exclusion of entire serum groups (Figure S7) or antigen variants (Figure S8), maps were constructed 85 excluding the specific sera or variant with 500 optimizations per map and the minimum column basis 86 set to "none".

87 Adding noise to antigen reactivity adds noise to all titers measured against the specific antigen, 88 whereas titer noise adds noise to a single measurement. The effects of which are shown in Figure S5. 89 The variants' positions were robust to titer noise (Figure S5B). The positions of non-omicron variants 90 varied by one to two antigenic units when adding noise to antigenic reactivity (Figure S5 A, C). Antigen 91 noise resulted in hemishering of BA.1 omicron, referring to two distinct optima for the variant's 92 position. The big effect on variant position by some noise can be understood if the added noise moves 93 an originally detectable titer below the detection threshold, or vice-versa. In case of the two omicron 94 sub-lineages, many titers were at the border or below detectable, hence adding artificial measurement 95 noise affected the positioning of these variants more than the other variants.

96 This can also be seen in Figure S6, where 1000 optimization runs were performed in which both 97 antigens and sera were randomly resampled with replacement (Figure S6A), only antigen variants were 98 resampled (Figure S6B) or individual serum samples were randomly sampled with replacement (Figure 99 S6C). Resampling variants had little effect on non-omicron variant positioning, but again two different 100 optima were found for BA.1 and BA.2 omicron. While serum bootstrapping had little effect on both 101 variants and sera (Figure S6C), variant bootstrapping demonstrated the uncertainty of BA.1 and BA.2 102 omicron convalescent sera positioning (Fig. S6 B), which had detectable titers against their root variant 103 but very low to non-detectable titers against other variants.

104 However, the distance of BA.1 and BA.2 omicron from vaccine sera and to each other remained stable.

To investigate which serum groups or variants had a particularly large impact on map topology, maps excluding single serum groups (Figure S7) or antigen variants (Figure S8) were constructed. Excluding BA.1 omicron conv. sera resulted in the effect on BA.1 and BA.2 omicron positions we observed when adding noise or resampling variants in map construction. Removal of other serum groups had no effect on variant positions.

Excluding the D614G and beta variant had a similar effect and moved both omicron variants to asecond optimal position (Figure S8).

112

### 113 Map cross-validation

114 For cross validation, *Racmacs'*<sup>1</sup> *dimensionTestMap* function was employed to optimize maps in 2

- dimensions with a test proportion of 0.1. 1000 replicates and 500 optimizations per replicate were
- 116 performed and the difference between measured and predicted titer calculated on the log<sub>2</sub> scale.

117 Briefly, 1000 optimizations runs were performed in which only 90% of titers were used for map 118 construction and the remaining 10% predicted by subtracting the Euclidean map distance for each 119 serum-antigen pair from the maximum log<sub>2</sub> titer of the specific serum. The mean difference between 120 measured and predicted log<sub>2</sub> titer was less one two-fold for detectable titers (Figure S9). However, this 121 differed largely across serum groups and antigen variants (Figure S10). The variability of BA.1 and BA.2 122 omicron conv. sera positions, and BA.1 and BA.2 omicron variant positions seen in the bootstrap map 123 resulted in much lower predicted than measured titers for these variants in the specific serum groups. 124 As before, if detectable titers against these variants were excluded from the map creation, their 125 position became inaccurate and hence sera with only detectable titers against BA.1 or BA.2 omicron,

- 126 which was true for the majority of BA.1 and BA.2 omicron conv. sera, could not be positioned either.
- 127

### 128 Individual antibody landscapes

Antibody landscapes<sup>2</sup> were constructed as described in *Materials & Methods*. With the map shown in 129 130 Figure 2 serving as base plane, antibody levels for each serum were plotted in a third dimension and a 131 continuous surface fitted to the available titer data. The reactivity profile of serum groups exposed to 132 a single variant, such as the convalescent and double vaccinated serum groups (Figure S11 A-J), was 133 assumed to adopt a cone like shape, with the highest point at the specific serum coordinate and a 134 constant decrease across antigenic space of one two-fold per antigenic unit.<sup>3</sup> This assumption does not 135 apply to serum groups exposed to more than one variant, as high titers against both encountered 136 variants are expected. For these groups (Figure S11 K-Q), each serum's coordinates were fitted to 137 optimize the serum's position in the map shown in Figure 2 and the surface's slope was fitted per 138 serum group, as the decrease of reactivity was assumed to be the same for individuals with the same 139 exposure history. The GMT landscapes show the average of all individual antibody landscapes.

140 The vaccine landscapes (Figure S11 A-D) were the most homogeneous in terms of titer magnitudes 141 within the serum group. Further, the different vaccine regiments elicted landscapes similar to each 142 other. The individual antibody profiles of most most convalescent groups were homogenous. With the 143 exception of one delta serum with high P.1.1 titers and two BA.2 conv. sera, all had highest titers 144 against their non-homologous variant. Antibody profiles such as these could be due to unknown prior 145 infections. The specific delta sample, however, was a PCR-confirmed first infection, suggesting a 146 different reason for the high titer against P.1.1. To investigate potential prior infection of the two cross-147 reactive BA.2 omicron conv. samples, maps were created without these two sera and antibody 148 landscapes fitted to their titers (Figure S12). The two sera did not impact the variant positions in the 149 map (Figure S12 A-C). Their antibody profiles, however, looked more similar to BA.2 omicron 150 breakthrough infections (sample G780) or reinfections (sample G776) than to BA.2 omicron first 151 infections (Figure S12 D). As the map without those two sera did not differ from the map including the 152 sera, the general conclusion of BA.2 omicron being positioned between pre-omicron variants and BA.1 153 omicron did not change.

154 The antibody landscapes after delta breakthrough were similar in both magnitude and shape 155 independent of Astra Zeneca or Pfizer vaccination (Figure S11 K-L), and were further comparable to BA.1 and BA.2 omicron breakthrough infections. Breakthrough landscapes after either omicron sub-156 157 lineage infection or vaccinated with prior infection and BA.1 omicron breakthrough were almost 158 indistinguishable both in titer magnitudes and landscape slope (Figure S11 M-P). All multi-exposure 159 landscapes, including BA.2 omicron reinfected landscapes (Figure S11 Q), exhibited a broad reactivity 160 profile, suggesting high degrees of cross-reactivity and good protection against variants within the 161 current mapped antigenic space.

162 The largest variation of individual landscapes was found in the BA.1 omicron breakthrough and 163 reinfected serum groups (Figure S11 M, O). To investigate the impact of number of vaccinations and 164 variant of prior infection, these two groups were split into subgroups and antibody landscapes were 165 constructed for each subgroup (Figure S13). This revealed that the landscape shape of double and 166 triple vaccinated individuals with BA.1 omicron breakthrough infection was almost identical, and the 167 observed variation was due to generally higher titers after three vaccine doses (Figure S13 A-B). The 168 shapes of reinfection landscapes, however, differed depending on the first encountered variant (Figure 169 S13 C-D). Prior infection with D614G resulted in antibody profiles similar to the vaccinated and 170 infected, and previous infection with vaccination groups, with reactivity peaking in the area of D614G 171 and slowly decreasing towards the omicron variants. Sera infected with delta followed by BA.1 omicron 172 had lower titers in the upper area of the map (D614G, alpha, beta), with individual landscapes having 173 higher BA.1 omicron titers than delta titers, resulting in a landscape shape almost mirroring the D614G 174 landscape. Only one sample was available with a prior alpha infection, which exhibited very low titers 175 against BA.1 omicron and much less cross-reactivity than the other BA.1 reinfection landscape.

#### 177 Supplementary Figures



178

Figure S1. Fold change neutralizing antibody titers gamma versus exposed variant. For each sample, the fold change titer in neutralizing antibodies (IC<sub>50</sub>) between gamma and the exposed variant was calculated. For first wave convalescent or two dose vaccinated individuals the D614G titers were used as exposed variant. Shown are individual samples and geometric mean change as bars. Numbers indicate the geometric mean change for each group.



Figure S2. Non-zoomed in version of the antigenic map. Virus variants are shown as colored circles,
sera as open squares with the color corresponding to the infecting variant. Vaccine sera are shown in

188 grey tones (from dark to light: mRNA-1273/mRNA-1273, BNT162b2/BNT162b2, ChAdOx-

189 S1/BNT162b2, ChAdOx-S1/ChAdOx-S1). The alpha + E484K variant is shown as smaller circle due to

190 its additional substitution compared to the alpha variant. The x- and y-axis represent antigenic

191 distances with one grid square corresponding to one two-fold serum dilution of the neutralization

titer. The map orientation within x- and y-axis is free as only relative distances can be inferred.

193



195

**Figure S3. Map dimensionality. A** Dimensionality test: RMSE between map and measured titers for detectable titers in 1 to 5 dimensions. Per dimension, 100 map replicates were constructed from 90% of measured titers with 1000 optimizations per replicate. The titers of the remaining 10% were predicted in each run and the RMSE calculated by comparing the predicted to the measured titers on the log<sub>2</sub> scale. **B, C** Side and front view of the map optimized in 3 dimensions with arrows pointing to the variants' position in the 2D map.



204 Figure S4. Goodness of map fit per serum group. The top panels show the correlation of detectable 205 measured and fitted titers in the 2D map with P.1.1 reactivity adjustment. Measured P.1.1 titers were 206 reduced by one two-fold to match the reactivity adjustment in the map. Map distances were converted 207 into log<sub>2</sub> titers by subtracting the Euclidean distance for each serum-antigen pair from the maximum 208 log<sub>2</sub> titer of the specific serum. The bottom panels show the residuals of measured against fitted titers 209 on the  $\log_2$  scale, light grey marks pairs with the measured titer below the assay detection threshold. 210 The mean and mean-centered standard deviation of differences between fitted and detectable 211 measured titers are given in the legend of each bottom row panel. This was done for the serum groups 212 used to construct the map: A mRNA-1273/mRNA-1273, B ChAdOx-S1/ChAdOx-S1, C ChAdOx-213 S1/BNT162b2, D BNT162b2/BNT162b2, E first wave conv., F alpha conv., G beta conv., H delta conv., I 214 BA.1 omicron conv., J BA.2 omicron conv.



- 216
- 217 Figure S5. Assessing map robustness to measurement uncertainty by bootstrapping. 1000 bootstrap
- 218 repeats were performed with 100 optimizations per repeat. Normally distributed measurement noise
- with a standard deviation of 0.7 was added to A titers and antigen reactivity, B only titers, and C only
- 220 antigen reactivity. The colored regions mark 68% (one standard deviation) of the positional variation
- 221 for each variant (filled shapes) and sera (open shapes). The colors correspond to the colors used in
- 222 Figure 2.



Figure S6. Assessing map robustness to the exclusion of measurements by bootstrapping. 1000 bootstrap repeats were performed with 100 optimizations per repeat. For each repeat, a random subset of titer measurements was taken with replacement. The bootstrapping was performed on A variants and sera, **B** only variants, and **C** only sera. The colored regions mark 68% (one standard deviation) of the positional variation for each variant (filled shapes) and sera (open shapes). The colors correspond to the colors used in Figure 2.



231

Figure S7. Assessing map robustness to the exclusion of sera. Each serum group was removed and the map reoptimized. Arrows point to the position of each variant in the map shown in Figure 2, for color correspondence refer to this map. A small arrow length indicates similar variant positions and map robustness to the exclusion of the particular serum group. Triangles point to sera positioned outside the plotting area. Maps without A mRNA-1273/mRNA-1273, B ChAdOx-S1/ChAdOx-S1, C ChAdOx-S1/BNT162b2, D BNT162b2/BNT162b2, E first wave conv., F alpha conv., G beta conv., H delta conv. LBA 1 omicron conv. LBA 2 omicron conv.

238 conv., I BA.1 omicron conv., J BA.2 omicron conv.



Figure S8. Assessing map robustness to the exclusion of antigen variant. Each antigen variant was removed and the map reoptimized. Arrows point to the position of each variant in the map shown in Figure 2, for color correspondence refer to this map. A small arrow length indicates similar variant positions and robustness to the exclusion of the particular antigen variant. Triangles point to sera positioned outside the plotting area. Maps without A D614G, B alpha (B.1.1.7), C alpha + E484K (B.1.1.7 + E484K), D gamma (P.1.1), E beta (B.1.351), F delta (B.1.617.2), G BA.1 omicron (B.1.1.529+BA.1), H

247 BA.2 omicron (B.1.1.529+BA.2).



Figure S9. Map cross-validation residual titers. 1000 optimization runs were performed with only 90% 250 251 of measured titers used for map construction by artificially masking 10% of measurements. The missing 252 log<sub>2</sub> titers were predicted by subtracting the Euclidean map distance for each serum-antigen pair from 253 the maximum log<sub>2</sub> titer of the specific serum. The difference between predicted and detectable 254 measured titers on the log<sub>2</sub> scale was calculated, the mean is indicated by the dashed line. The mean and mean-centered standard deviation are given. The upper x-axis limit has been set to 15 for plotting 255 256 purposes, very few residuals in the BA.1 and BA.2 omicron convalescent groups were larger than 100, 257 due to inaccurate positioning of sera.





*Figure S10: Map cross-validation predicted vs. measured titers. Figure caption on next page.* 

Figure S10. Map cross-validation predicted vs. measured titers. 1000 optimization runs were 261 262 performed with only 90% of measured titers used for map construction by artificially masking 10% of 263 measurements. The missing log<sub>2</sub> titers were predicted by subtracting the Euclidean map distance for each serum-antigen pair from the maximum log<sub>2</sub> titer of the specific serum. The detectable measured 264 265 over predicted log2 titers are shown per serum group and antigen variant. No BA.1 omicron titers were 266 above the detection threshold in the alpha convalescent and AZ/AZ vaccinated serum groups. The 267 lower x-axis limit has been set to -10 for plotting purposes, very few residuals in the BA.1 and BA.2 268 omicron convalescent groups were larger than 100, due to inaccurate positioning of sera. Many 269 thresholded titers in the original dataset for the omicron variants and in the omicron serum group 270 resulted in inaccurate predictions if the detectable measurements were masked in map making.

271



274 Figure S11. Individual serum antibody landscapes. The colored surfaces represent the GMT antibody 275 landscapes of the different serum groups, the grey transparent surfaces individual serum landscapes. 276 Serum reactivity bias was adjusted for GMT calculation as described in (Wilks et al., 2022). The map 277 shown in Figure 2 serves as base plane, the z-axis reflects log<sub>2</sub> titers with each two-fold increase marked 278 starting from titer 20. The grey plane at titer 50 serves as reference. The impulses show serum group 279 GMTs for each variant. The landscapes are shown for the following serum groups: A mRNA-1273/mRNA-1273, B ChAdOx-S1/ChAdOx-S1, C ChAdOx-S1/BNT162b2, D BNT162b2/BNT162b2, E first 280 281 wave conv., F alpha conv., G beta conv., H delta conv., I BA.1 omicron conv., J BA.2 omicron conv., K 282 AZ/AZ + delta breakthrough, L BNT/BNT + delta breakthrough, M BA.1 omicron breakthrough, N BA.2 283 omicron breakthrough, O BA.1 omicron reinfection, P Vaccinated, previous non-omicron infection and BA.1 omicron infection, Q BA.2 omicron reinfection. Serum coordinates and landscapes for K-Q were 284 285 fitted as described in Materials & Methods.



287

Figure S12. Testing effect of cross-reactive BA.2 omicron convalescent sera on map and landscape. 288 A Map in Figure 2 shown with two cross-reactive BA.2 convalescent sera (G778, G780) highlighted in 289 290 dark purple. B A map was constructed excluding these two sera to test their effect on variant 291 positioning. C Map in B with arrows pointing to the variant's position in map A. The small arrows 292 indicate that the two cross-reactive samples do not impact BA.2 positioning. D GMT Antibody 293 landscapes of serum groups which encountered BA.2 omicron (Vacc + BA.2 omicron breakthroughs, 294 BA.2 omicron reinfected, BA.2 convalescents, (Fig. S11 N, Q, J)) and individual landscapes of the two 295 BA.2 convalescent samples with high titers against non-omicron variants (G778, G780). The slope of 296 the BA.2 conv. landscape, excluding the two cross-reactive samples, was set to 1, all other slopes and 297 serum coordinates were fitted as described in Material & Methods. The map shown in panel B serves 298 as base plane, the z-axis reflects log<sub>2</sub> titers with each two-fold increase marked starting from titer 20. 299 The grey plane at titer 50 serves as reference.



Figure S13. Variability of BA.1 omicron multi-exposure landscapes. Individual (transparent) and GMT (solid) antibody landscapes for the Vacc + BA.1 omicron (A-B), BA.1 omicron reinf. (C-E) and Vacc + BA.1 omicron reinf. (D) after subsetting by number of vaccinations and prior infection (Fig. S11 M, O). The map in Figure 2 serves as base plane, the serum coordinates per serum and landscape slopes per additional serum group were fitted as described in *Materials & Methods*. Serum reactivity bias was adjusted for GMT calculation as described in <sup>3</sup>. The z-axis reflects log<sub>2</sub> titers with each two-fold increase marked starting from titer 20. The grey plane at titer 50 serves as reference.

# 310 Supplementary Tables

# 312 Table S1. Patient Characteristics

Study cobort	number of	vaccination -(+/-)	Variant of	infection	Mean age	% female (N)	
Study conort	participants		first	second	(years) ± SD		
Single exposure							
First wave convalescent	10	-	ancestral	-	51.6 ± 11.8	60.0 (6)	
Alpha convalescent	10	-	alpha	-	49.1 ± 14.3	80.0 (8)	
Beta convalescent	8	-	beta	-	79.8 ± 9.5	50.0 (4)	
Delta convalescent	7	-	delta	-	27.3 ± 10.3	42.9 (3)	
BA.1 convalescent	18	-	BA.1 omicron	-	47.0 ± 17.2	61.1 (11)	
BA.2 convalescent	12	-	BA.2 omicron	-	35.8 ± 14.9	50.0 (6)	
Double exposure							
BA.1 reinfected	15	-	ancestral (n=5) alpha (n=1) delta (n=9)	BA.1 omicron	35.0 ± 16.9	72.7 (8)	
BA.2 reinfected	3	-	ancestral (n=1) delta (n=2) BA.2 c		34.7 ± 6.2	66.7 (2)	
mRNA-1273/ mRNA-1273	10	+	-	-	35.4 ± 9.4	60.0 (6)	
AZ/AZ	10	+	-	-	37.3 ± 9.3	80.0 (8)	
AZ/BNT	10	+	-	-	32.8 ± 4.1	70.0 (7)	
BNT/BNT	11	+	-	-	36.1 ± 10.6	63.6 (7)	
≥ Triple exposure							
Vacc + BA.1	14	+	omicron (BA.1)	-	36.5 ± 16.8	57.1 (8)	
Vacc + BA.2	8	+	omicron (BA.2)	-	32.8 ± 4.1	62.5 (5)	
Vacc + BA.1 reinfected	11	+	ancestral (n=4) alpha (n=1) delta (n=6)	BA.1 omicron	36.4 ± 16.8	54.5 (6)	
AZ/AZ + delta	6	+	delta	-	30.3 ± 4.6	100.0 (6)	
BNT/BNT + delta	22	+	delta	-	50.7 ± 14.4	59.1 (13)	

	Comparison of BA.2 titers against <sup>\$</sup>						
Study cohort	D614G	Alpha	Alpha + E484K	Beta	Gamma	Delta	BA.1 Omicron
Single exposure							
BA.2 convalescent	ns	*	*	***	*	ns	ns
First wave convalescent	**	*	ns	ns	**	*	ns
Double exposure							
AZ/AZ + delta	ns	ns	***	ns	ns	ns	ns
BNT/BNT + delta	***	****	***	ns	****	***	ns

Table S2. Statistics for neutralizing antibody titers against indicated variant compared to BA.2 omicron.

<sup>\$</sup> using non-parametric repeated measures ANOVA with Friedman's test for multiple comparisons

# Table S3. Representativeness of study.

Disease, problem, or condition under	BA.2 omicron differs immunologically from both BA.1			
investigation	omicron and pre-omicron variants			
Special considerations related to				
Sex	Female study participants were slightly			
	overrepresented. Seroprevalence through infection in			
	Austria is similar among males and females. <sup>4</sup> A study			
	found equal titers of neutralizing antibodies between			
	male and female participants. <sup>5</sup>			
Age	Age was similar in all vaccinated groups; however, in			
	unvaccinated convalescent there were differences.			
	This might influence absolute titers of neutralizing			
	antibodies; however, the ratio between the different			
	variants should not be affected by this.			
Ethnicity	Majority of population in Tyrol/Austria is white			
Geography	Rates of vaccination and prior infection vary			
	throughout the world. Austria has a vaccination rate			
	of 73.1% (29.04.2022). <sup>6</sup> Seroprevalence in Tyrol has			
	increased in a study among blood donors (healthy			
	adults 18-70 years) from 3.4% in June 2020 to 82.7%			
	in September 2021. <sup>7</sup>			
Durability of cross-neutralizing	Some of the samples from convalescent individuals			
antibodies	were collected shortly after infection (2-4 weeks) and			
	therefore conclusions over longevity of these			
	antibodies are limited.			
Overall representativeness of this study	Small sample size and retrospective study design are			
	major limitations of the current study. Further studies			
	are needed to include newer omicron sub-variants			
	into the antigenic maps such as BA.4, BA.5 and			
	BA.2.12.1, which are currently rising in South Africa			
	and the USA.			

### Supplementary References

- 1. Wilks S. Racmacs: R Antigenic Cartography Macros. (https://acorg.github.io/Racmacs/index.html).
- 2. Fonville JM, Wilks SH, James SL, et al. Antibody landscapes after influenza virus infection or vaccination. Science 2014;346(6212):996-1000. DOI: doi:10.1126/science.1256427.
- 3. Wilks SH, Mühlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. bioRxiv 2022:2022.01.28.477987. DOI: 10.1101/2022.01.28.477987.
- 4. Knabl L, Mitra T, Kimpel J, et al. High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. Commun Med (London) 2021;1(1):4. (In eng). DOI: 10.1038/s43856-021-00007-1.
- 5. Pichler D, Baumgartner M, Kimpel J, et al. Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age. The Journal of infectious diseases 2021;224(5):764-770. (In eng). DOI: 10.1093/infdis/jiab300.
- 6. Our World in Data. (<u>https://ourworldindata.org/covid-vaccinations#what-share-of-the-population-has-completed-the-initial-vaccination-protocol</u>).
- Siller A, Seekircher L, Wachter GA, et al. Seroprevalence, waning, and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: Large-scale study of 35,193 blood donors conducted between June 2020 and September 2021. medRxiv 2021:2021.12.27.21268456. DOI: 10.1101/2021.12.27.21268456.